机译
黑素细胞性皮肤肿瘤：遗传畸变和临床病理分类。
- 作者：Carmelo Urso
- 刊名：Dermatology Practical Conceptual
- 2020年第1期
摘要：Melanocytic tumors are currently classified as , considered benign; , considered malignant; and , considered borderline tumors [ ]. However, recent studies on the genetic aberrations tend to make this classification problematic. In fact, the genomic analysis shows that both nevi and melanomas present mutations activating a certain number of growth-promoting signaling pathways. Tumors labeled as nevi and considered to be benign generally have a single or a small number of pathogenic mutations, often activating the MAP-kinase pathway ( ), but no apparent additional genomic alterations. Tumors labeled as melanomas and considered to be malignant may harbor the same driver mutations detected in those labeled nevi, associated with a variable, generally high, number of additional mutations tending to ablate tumor-suppression mechanisms and to activate additional oncogenic pathways, including , , , and -promoter mutations ( ). Tumors histologically regarded as problematic, sometimes termed or , harbor the same driver mutations detected in “nevi” and in “melanomas,” but a lower number of promoting mutations than “melanomas” [ – ]. The study of the distribution of pathogenic mutations has suggested they may occur in certain characteristic sequences [ ]. The initial event is often represented by a single mutation, which appears to be different in the different types of lesions: in common nevi; in some congenital and some acquired nevi; or in blue nevi; kinase fusions of , or in Spitz nevi; and kinase fusion of in spindle cell nevi of Reed [ , – ]. Moreover, in some -mutated neoplasms, more specific histological and biological characteristics may be produced by a supervening driver mutation, just as mutation in inactivated nevus, in deep penetrating nevus, and in epithelioid blue nevus/pigmented epithelioid melanocytoma [ – ]. Subsequently, other driver and/or promoting mutations may be progressively acquired, because driver mutations tend to induce an increase of cellular proliferation and, consequently, an increase of the probability that additional mutations occur. These supervened genomic aberrations may be ineffective or capable to alter, lightly or severely, a certain number of cell proliferation control mechanisms. If effective, they may lead to an additional enhancement of cell proliferation and, consequently, to an additional probability that other mutations take place, and so forth [ – ]. Therefore, in any given tumor, the total amount of the acquired mutations produces a certain risk of neoplastic progression, parallel to a certain risk of unfavorable events (recurrences, local and distant metastases, or death). This dual risk can be considered the of the tumor, definable as the probability that a certain number of adverse events may occur and directly proportional to the global pathogenic mutational burden. When genetic alterations are small in number, limited to the driver mutation or few more, this potential is low or very low, adverse events are rare or very rare, and, clinically, the tumor appears as benign. When genetic alterations are numerous, including driver and promoting mutations, the malignant potential is high, adverse events are frequent, and, clinically, the tumor appears as malignant. Of course, all intermediate cases may exist, because the malignant potential may theoretically assume every value between a minimum value (>0) and a maximum one (=100). The lowest possible value is >0, because all melanocytic tumors harbor at least 1 genomic alteration affecting the proliferation control mechanisms, and this inevitably implies a certain risk (risk 0 is to be reserved to the healthy skin, in which melanocytes harbor no pathogenic mutations). In sum, there do not seem to exist tumors with no chromosomal aberrations and consequently with no risk (risk = 0) and, at the same time, there seem to exist very few, if any, tumors harboring the of the possible chromosomal aberrations and, consequently, with the maximum possible risk (risk = 100). Tumors tend to show a certain variable number of pathogenic mutations and consequently may have all possible levels of risk, the malignant potential ranging between >0 and 100.
